A Phase 2 interventional study of Buprenorphine (BUP) and Hydromorphone in Acute Pain, sponsored by Stanford University. Not yet recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-17.
Sponsored by Stanford University · Phase 2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Acute Pain by Stanford University — 3 open to participants now, 4 under way, none of them phase 3. Acute Pain · Stanford University.
Among the 10 studies in Acute Pain by Stanford University, this one is the only one that started in 2027, is the only one in phase 2, and was the 10th registered.
1,075 studies on the registry are indexed under Acute Pain; 167 are open to participants now.
Browse Acute Pain studies →3 of the 10 studies in Acute Pain by Stanford University are open now, in 1 country. Recruiting first, the newest first:
Stanford University · Sites in United States
Ages 12–18
Stanford University · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 103 Acute Pain studies recruiting now, 40 (39%) set no upper age limit and 50 (49%) stop at 75 or younger; 21 take children under 18; 24 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2017; this study’s year is marked. 1 started in 2027.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 136 is above the median of 86 across 903 interventional studies indexed under Acute Pain.
Median enrollment 52 across the 8 interventional studies, 272 across the 2 observational. Of the 4 that completed or were terminated, 2 (50%) have results posted.
This tab as a report to print or save as PDF → With an account.
Stanford University is the lead sponsor of 2,171 studies on the registry; 432 are open to participants now.
Of its 267 completed or terminated interventional studies of FDA-regulated products, 207 (78%) have results posted.
2 of the studies in Acute Pain by Stanford University that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07821931Stanford UniversitySuzetrigine in Tonsillectomy for Opioid-sparing Pain Management | 2027-06 |
| NCT06093477Stanford UniversityStudying Melatonin and Recovery in Teens | 2027-06-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Acute Pain by Stanford University, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to compare low-dose IV buprenorphine with IV hydromorphone for adults with undifferentiated acute pain in the Stanford Emergency Department.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraindication
A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The participants receive a single intravenous (IV) 90 mcg dose of Buprenorphine for acute pain in the emergency department (ED). Rescue IV hydromorphone 0.5 mg may be administered after 30 minutes if needed for acute pain.
Drug: Buprenorphine (BUP)
The participants receive a single IV dose of 0.5 mg hydromorphone for acute pain in the ED. Rescue IV hydromorphone 0.5 mg may be administered after 30 minutes if needed for acute pain.
Drug: Hydromorphone
Buprenorphine is a partial mu-opioid receptor agonist with a ceiling effect on respiratory depression and a longer duration of action than full agonists.
Also known as: Buprenex
Hydromorphone is a full mu-opioid receptor agonist and a commonly used standard IV opioid analgesic in emergency department practice.
Also known as: Dilaudid
Change in pain intensity on the 0-10 Numeric Rating Scale (NRS)
Pain intensity is rated on the 0-10 NRS (0 = no pain, 10 = worst pain imaginable). Outcome is the change score (60-minute NRS minus baseline NRS), with a more negative change indicating greater pain relief.
Time frame: Baseline (pre-randomization), and up to 60 minutes after drug administration
Plan to share: No
Start is estimated for Jul 2027; primary completion for Jul 2028, 12 months later.
Of 40 phase 2 interventional studies under Acute Pain, half reached primary completion within 10 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 23. This study's planned 12 months is above that.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is not yet recruiting, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.